Primary Outcome Measures Dose-limiting Toxicity [ Time Frame: First 21 days of treatment. ] The incidence of DLTs during the DLT assessment period. Frequency and Severity of Adverse Events (AE) [ Time Frame: Screening to 90 days from last dose. ] The incidences and percentages of patients experiencing AEs summarized by NCI CTCAE version 5.0 grade and by[…]
Mesothelioma
OT-101 Useful for COVID-19 and Cancers Like Mesothelioma
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective[…]
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Primary Outcome Measures Phase 1: [ Time Frame: 28 days ] To determine the MTD and dosing schedule of TNG908 Phase 2: [ Time Frame: 16 weeks ] To assess anti-neoplastic activity of TNG908 in patients with MTAP-deleted advanced solid tumors by RECIST v1.1 Secondary outcome Measures Phase 1: [ Time Frame: 16 weeks ] To assess preliminary evidence of anti-neoplastic activity[…]
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Primary Outcome Measures Safety and tolerability of IK-930 [ Time Frame: Through study completion, an average of 36 months ] The frequency and severity, incidence of treatment-emergent and treatment-related adverse events using NCI-CTCAE v5.0 Occurrence of Dose Limiting Toxicity during first treatment cycle [ Time Frame: Approximately 1 year ] RP2D and/or MTD of IK-930 [ Time Frame: Approximately 1 year ][…]
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Primary Outcome Measures Phase 1: Number of Patients who Experience Dose-Limiting Toxicity [ Time Frame: 21 days ] Phase 1/1B: Number of patients who experience a treatment-related adverse event [ Time Frame: Up to 2 years ] Phase 2: Objective response rate (ORR) [ Time Frame: 2 years ] Phase 2: Duration of response (DOR) [ Time Frame: 2 years ] Phase 2: Progression free survival[…]
Tremelimumab and Durvalumab Combination Can Improve Mesothelioma Survival
Studies show that durvalumab and tremelimumab work very well together while treating mesothelioma. A phase I clinical trial was performed at the Baylor College of Medicine in conjunction with Baylor St. Luke’s Medical Center. Durvalumab is an immunotherapy drug known as a PD-1/PD-L1 checkpoint inhibitor. It works by blocking the[…]
A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
Primary Outcome Measures Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), changes in laboratory values, vital signs and electrocardiogram (ECG) [ Time Frame: Cycle 1 Day 1 to 30 days after the last dose of HFB200301 (each cycle is 28 days), assessed up to 3 years ] To determine[…]
The immunotherapy Drug Bevacizumab Can Improve Survival in Mesothelioma Patients
An immune system boosting therapy could potentially be used to treat mesothelioma. For a long period of time, chemotherapy drugs have been the standard drug to fight mesothelioma, but researchers believe bevacizumab could change this and be used alongside standard mesothelioma treatments. Chemotherapy is popular with doctors, but chemotherapy drugs[…]
Different Levels of Pleurectomy and Decortication Surgery can Save Mesothelioma Patients’ Lives
Italian researchers believe that lung sparing surgery can improve survival in mesothelioma patients, even when surgeries are more conservative. Pleurectomy and decortication is the surgery that spares the lungs. It is less comprehensive than the surgery that removes the lungs, which also makes it less dangerous to patients. Doctors at[…]
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Primary Outcome Measures Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 21 Days ] A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by[…]
Skip to content